Initiation of second-line type 2 diabetes treatment is lagging while A1c at the time it is introduced is climbing. The author of a new study highlights his findings on clinical inertia.
Patients with type 2 diabetes (T2D) who remain above recommended glycemic targets are at increased risk for a myriad of well-known complications, elevating the importance of early, aggressive treatment.
In this interview with Patient Care© Online, Sridharan Raghavan, MD, PhD, assistant professor of medicine in the Department of Medicine at the University of Colorado Anschutz Medical Campus, reviews the findings of a study he recently led on trends in timing of and A1c level at initiation of second-line therapy among US veterans newly diagnosed with type 2 diabetes.
The findings reinforce the subtle but steady erosion in therapeutic progress driven by clinical inertia in US health care.
Sridharan Raghavan, MD, PhD is an assitant professor and clinical investigator in the division of hosptial medicine, University of Colorado Denver, Anschutz Medical Campus and a clinician at the Rocky Mountain Regional Veterans Affairs Medical Center in Aurora, Colorado.
Reference: Raghavan S, Warsavage T, Liu WG, et al. Trends in timing of and glycemia at initiation of second-line type 2 diabetes treatment in US adults. Diabetes Care. Published online ahead of print March 28, 2022;dc212492.